Yuhan Corp
000100
Company Profile
Business description
Yuhan Corp is a pharmaceutical company. The core business of the company is classified as primary and specialty care, dietary supplements, household and animal care, and contract manufacturing of active pharmaceutical ingredients. The company offers one-stop custom synthesis services from research and development to commercial production of active pharmaceutical products (APIs) and intermediates for the following disease treatments: antivirals (HCV and HIV), antibiotics, antihistamines, antidiabetics, beta-lactamase inhibitors, CNS intermediates, and PEGylated compounds for international markets.
Contact
74, Noryangjin-ro
Dongjak-gu
Seoul
KORT: +82 28280181
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
2,117
Stocks News & Analysis
stocks
Is this still an ASX share to own forever?
Find out how this defensive player has fared after earnings.
stocks
After earnings, is Nvidia stock a buy, a sell, or fairly valued?
No signs of a slowdown in demand for Nvidia’s chips, and the long-term picture looks bright.
stocks
Short-term pain for long-term gain for undervalued ASX share
Cost reductions lower our profit estimates but should lead to improved long-term outcomes.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,091.40 | 51.20 | 0.57% |
| CAC 40 | 7,698.92 | 20.79 | -0.27% |
| DAX 40 | 23,770.33 | 175.53 | 0.74% |
| Dow JONES (US) | 45,526.84 | 255.61 | 0.56% |
| FTSE 100 | 9,216.87 | 38.88 | 0.42% |
| HKSE | 25,058.51 | 284.92 | -1.12% |
| NASDAQ | 21,602.92 | 105.19 | 0.49% |
| Nikkei 225 | 42,580.27 | 641.38 | 1.53% |
| NZX 50 Index | 13,133.20 | 58.39 | 0.45% |
| S&P 500 | 6,479.95 | 31.69 | 0.49% |
| S&P/ASX 200 | 8,826.50 | 59.20 | 0.68% |
| SSE Composite Index | 3,765.88 | 47.68 | -1.25% |